Rose McNulty

Chimeric antigen receptor (CAR) T-cell therapies have shown efficacy and safety for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), but barriers to referral may obstruct patient access to them.

A secondary analysis of the phase 3 TOURMALINE-MM4 trial found that ixazomib as postinduction maintenance therapy for multiple myeloma produced a progression-free survival (PFS) benefit vs a placebo across age and frailty subgroups.

A study of patients with acute myeloid leukemia (AML) in first remission found that the presence of certain variants indicative of measurable residual disease ahead of allogeneic hematopoietic cell transplant (HCT) was associated with relapse and worse survival.

A white paper published by the Institute for Clinical and Economic Review (ICER) established a series of recommendations and guidelines for health technology assessment that aim to address health care disparities.

Exposure to pets during fetal development or early infancy was associated with reduced instances of food allergies in young children, with different pet exposures potentially reducing the incidence risk of certain allergen types.

Patients who underwent sublobar resection and those who underwent more invasive lobectomy for early-stage non–small cell lung cancer (NSCLC) showed similar overall and disease-free survival outcomes in a recent study.

Treatment with relugolix and concomitant therapies for prostate cancer showed similar safety and efficacy to relugolix alone in a recent study.

Assessing both physical and emotional functioning scales within cancer quality-of-life questionnaires at diagnosis may help predict survival in patients with lung cancer, a recent study found.

Idecabtagene vicleucel (ide-cel) led to significantly longer PFS and better therapy responses than standard regimens for patients with triple-class–exposed relapsed and refractory multiple myeloma.

A review based on an expert panel discussion highlights a need for the inclusion of older patients in studies of immune checkpoint inhibitors for the first-line treatment of advanced non–small cell lung cancer (NSCLC).

Patients with prostate cancer who were treated with brachytherapy boost showed improved survival compared with those treated with external beam radiotherapy in a recent study.

A recent study suggests that sleeve lobectomy is safe to perform in patients with non–small cell lung cancer who received neoadjuvant therapy.

A recent study found that infection is a significant burden in patients with multiple myeloma who receive bispecific antibodies, and viral infections are the most common culprits.

The survival benefits of immune checkpoint inhibitors varied in young patients versus older patients with advanced non–small-cell lung cancer, a recent study found.

A prespecified overall survival analysis of the phase 3 ZUMA-7 trial found that axicabtagene ciloleucel (axi-cel) led to better outcomes vs the historical standard of care for relapsed or refractory large B-cell lymphoma (R/R LBCL).

A recent study found that microbiome-based biomarkers may be useful in predicting patient responses to CAR T-cell therapy for non-Hodgkin lymphoma.

Extended follow-up data from the ProtecT trial highlight the importance of weighing the risks associated with radical treatment versus active surveillance for newly diagnosed localized prostate cancer.

Different methods of DNA collection and needle sizes led to varied next-generation sequencing success rates among patients with lung cancer in a recent study.

The majority of CAR T-cell therapy recipients developed a humoral immune response to vaccination against SARS-CoV-2 in a recent study, with a more robust vaccine schedule linked to higher antibody titers.

A recent study identified disparities in cachexia incidence among patients with stage IV non–small cell lung cancer (NSCLC) across different racial, ethnic, and socioeconomic groups.

There may be discrepancies in the types of information patients want and the information they receive when multiple myeloma treatment decisions are made, a recent study found.

A session at the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit highlighted ongoing issues in oncology policy and payment, from the Cures 2.0 Act to 340B drug reimbursement.

A meta-analysis and review of 9 randomized trials found high-quality evidence demonstrating the benefits of dupilumab in patients with severe atopic dermatitis.

A session at the ACCC 2023 Annual Meeting and Cancer Center Business Summit addressed the promise and potential drawbacks of multicancer early detection (MCED) testing for patients in the primary care setting.

In the first keynote session at the ACCC 2023 Annual Meeting and Cancer Center Business Summit, the history of CRISPR genome editing and its potential in cancer and other settings took center stage.

The extended follow-up results are consistent with the primary analysis of the CLEAR trial, supporting the increased efficacy of first-line lenvatinib plus pembrolizumab compared with sunitinib in patients with advanced renal cell carcinoma.

Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, discusses how the pandemic changed clinical trial enrollment in the leukemia/lymphoma space.

The Association of Community Cancer Centers (ACCC) 49th Annual Meeting and Cancer Center Business Summit will feature presentations and interactive workshops centered on the latest in technology, care delivery, and payment issues in oncology.

Eric Rackow, MD, cofounder and executive chairman of eFamilyCare, discusses the importance of virtual support for family caregivers.

Children with acute lymphoblastic leukemia living in US-Mexico border regions had worse 5-year survival rates compared with children living in other parts of Texas, a recent study found.